Minute Insights

The Paris-based start-up has picked up a CE mark for the latest generation of its Maestro system, a tool designed to make laparoscopic surgery easier and safer.

The two tech companies – one software giant, the other focused on oncology – will work together on what will likely be the largest artificial intelligence model of its kind.

The genome-sequencing giant has named Jacob Thaysen, who brings extensive experience from Agilent, as its new leader.

The pure-play software company, which has developed a tool to record and monitor patients’ coughs, has signed a partnership to integrate its technology into a wearable.

The sequencing technology company, led by an interim CEO, is further shuffling its leadership following the announcement of disappointing mid-year results.

Cooper announced a plan to buy Cook’s reproductive health business in February. The deal would have been worth $675m up front and $200m in four annual installments. The US FTC determined the deal would have impaired competition in the reproductive health market.

Illumina sued Guardant last year, claiming Guardant’s founders stole trade secrets related to blood biopsy diagnostics. The companies have agreed to drop that dispute and share specimen samples for cancer research.

Surgalign was forced into bankruptcy after falling foul of the US SEC, leaving Audmedics to pick up its digital health assets for the bargain price of $900,000.

ViewRay will continue to maintain its MRI-guided radiation therapy systems at customer sites, but filed for Chapter 11 bankruptcy protection and is planning to sell the business’ assets.

Medtronic has secured coverage to market its recently approved MiniMed 780G insulin pump to eligible Medicare and Medicare Advantage beneficiaries, opening access to more patients after a long delay in bringing the device to the US market.

Coloplast expects Kerecis' rapid growth to justify the high price of the acquisition. The Icelandic company's skin-substitute products are made from minimally processed cod skins.

Dexcom wins Health Canada approval to market its G7 CGM in Canada, following announcements of its ambitious R&D map to expand into metabolic health and new product plans for consumers and the diabetes markets at ADA.

The two companies will merge following a cash-for-shares offer from restore3d being accepted by Conformis’ board.

Medtronic, an investor in Allurion, will help distribute Allurion’s inflatable gastric balloon in specific regions.

The Utah company acquired dialysis and biopsy devices from AngioDynamics for $100m and an access catheter from Bluegrass Vascular for $32.5m.

The company will create a handheld version of its FAIMS technology, to be used in rapid testing for transmissible illnesses in combat scenarios.